Holen Sie sich die Stockscreener-App
32.46
2.87%
-0.96
Handel nachbörslich:
32.46
Rigel Pharmaceuticals Aktie (RIGL) Neueste Nachrichten
Rigel Pharmaceuticals (RIGL) Advances 2.13%: Testing Resistance at $32.26Leveraged ETF Flow - newsline.com
RIGEL PHARMACEUTICALS INC (RIGL) Stock Chart - ChartMill
Why (RIGL) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Rigel Pharmaceuticals Edges Higher: Testing Key Resistance at $31.61Gap Up Stocks - newsline.com
Insider Move: Dean Schorno Exercises Options, Realizing $52K At Rigel Pharmaceuticals - Benzinga
Rigel Pharmaceuticals (RIGL) CFO exercises options and withholds shares for taxes - Stock Titan
Rigel (NASDAQ: RIGL) EVP uses shares to cover tax obligations - Stock Titan
Rigel (RIGL) CMO uses 850 shares to cover stock tax liability - Stock Titan
RIGEL (RIGL) CEO uses 2,424 shares for tax-withholding, retains large stake - Stock Titan
RIGEL (RIGL) EVP Furey uses 877 shares to cover tax obligations - Stock Titan
RIGL Reiterated by HC Wainwright & Co. -- Price Target Maintained at $57 - GuruFocus
Rigel Pharmaceuticals Gains Momentum, Testing Key Resistance at $32.14Straddle Setup - newsline.com
RIGL Stock Price, Quote & Chart | RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) - ChartMill
Insider Sell: Kamil Ali-jackson Sells 2,500 Shares of Rigel Phar - GuruFocus
Insider Sell: Kamil Ali-jackson Sells 2,500 Shares of Rigel Pharmaceuticals Inc (RIGL) - GuruFocus
Understanding Momentum Shifts in (RIGL) - Stock Traders Daily
Rigel Pharmaceuticals director Ali-Jackson Kamil sells $72,925 in stock By Investing.com - Investing.com India
Rigel Pharmaceuticals director Ali-Jackson Kamil sells $72,925 in stock - Investing.com
Rigel Pharmaceuticals (RIGL) director sells 2,500 shares in open-market trade - Stock Titan
Rigel Pharmaceuticals, Inc. (RIGL) Latest Stock News & Headlines - Yahoo Finance
Rigel Pharmaceuticals (RIGL) CEO to Present at Jefferies Global Healthcare Conference - GuruFocus
Rigel Pharmaceuticals to Present at Jefferies Global Healthcare Conference on May 27, 2026 - geneonline.com
Rigel (RIGL) Gains Momentum as Kissei Submits NDA for Rezlidhia in Japan - GuruFocus
Rigel Pharmaceuticals (RIGL) Gains Nearly 2% as Stock Tests Key Resistance Near $31.24High Reward Trades - thelegaladvocate.com
Rigel Pharmaceuticals Acquires Global Rights to Veppanu in $85 Million Deal, Targeting ESR1-Mutated Breast Cancer - geneonline.com
Biotech CEO to give Rigel company overview at Jefferies healthcare conference - Stock Titan
Rigel to Present at the Jefferies Global Healthcare Conference – Company Announcement - Financial Times
[144] RIGEL PHARMACEUTICALS INC SEC Filing - Stock Titan
RIGL Technical Analysis | Trend, Signals & Chart Patterns | RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) - ChartMill
Rigel Pharmaceuticals Presents GAVRETO Phase 3 Data at ASCO 2026 - Intellectia AI
Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress - PR Newswire
Rigel Gains 77% in 3 Months: Is This an Indication to Buy the Stock? - MSN
Pfizer’s VEPPANU License With Rigel Adds New Angle To PFE Story - Yahoo Finance
Rigel Pharmaceuticals, Inc. (RIGL) M&A CallSlideshow (NASDAQ:RIGL) 2026-05-20 - Seeking Alpha
Rigel Shareholders Approve Equity Plans and Board Slate - TipRanks
Rigel (RIGL) investors back equity plan, ESPP and auditor at 2026 meeting - Stock Titan
Rigel Pharmaceuticals Highlights Growth Amid Rising Costs - TipRanks
Pfizer Keeps Oncology Upside As Rigel Takes VEPPANU PROTAC Lead - simplywall.st
Board member gets 5,750 RSUs at Rigel Pharmaceuticals (RIGL) - Stock Titan
Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug - MSN
Rigel Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Rigel Pharmaceuticals Q3 2025 Earnings Preview - MSN
Director Walter H. Moos receives 5,750-share RSU award at RIGEL (NASDAQ: RIGL) - Stock Titan
Avoiding Lag: Real-Time Signals in (RIGL) Movement - Stock Traders Daily
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GuruFocus
Pfizer, Arvinas ink licensing deal with Rigel for breast cancer therapy - MSN
Rigel Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Rigel Pharmaceuticals (RIGL) Is Up 11.4% After Licensing FDA‑Approved Breast Cancer Drug VEPPANU - simplywall.st
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer - Yahoo Finance
Armistice Capital (RIGL) reports 1.28M shares, 6.93% stake - Stock Titan
Weekly Buzz: Lilly Posts Positive Trial Data, Rigel Licenses PROTAC Drug, BMY Strikes $15.2B Deal - RTTNews
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):